PD-Inhibitor (Nivolumab) and Ipilimumab followed by Nivolumab vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]

This study is being done to answer the following question: Can we prolong life for patients with
advanced kidney cancer, by adding a drug called cabozantinib to another treatment after
receiving the standard treatment?

We are doing this study because we want to find out if this approach is better or worse than the
usual approach for your advanced kidney cancer. The usual approach is defined as care most
people get for advanced kidney cancer.